In this piece, we will take a look at the 5 best dialysis and kidney disease stocks to buy. To see more such companies, go directly to 10 Best Dialysis and Kidney Disease Stocks to Buy.
5. Boston Scientific Corporation (NYSE:BSX)
Number of Hedge Fund Holders In Q2 2023: 69
Market Capitalization: $73.9 Billion
Founded in 1979 and headquartered in Massachusetts, Boston Scientific Corporation (NYSE:BSX) ranks 5th in our list of the best dialysis and kidney disease stocks to buy. The company strives to provide innovative and differentiated dialysis solutions to its customers. Boston Scientific Corporation (NYSE:BSX) offers treatment for Hemodialysis end-stage renal patients. The firm also provides numerous treatment plans for kidney stones.
As of Q2 2023, 69 out of the 910 hedge funds part of Insider Monkey’s database had held a stake in the company. Boston Scientific Corporation (NYSE:BSX)’s largest hedge fund shareholder is Ken Griffin’s Citadel Investment Group due to its $836 million stake.
4. Humana Inc. (NYSE:HUM)
Number of Hedge Fund Holders In Q2 2023: 70
Market Capitalization: $65 Billion
With a market capitalization of $65 billion, Humana Inc. (NYSE:HUM) provides a renal disease management program for patients with late-stage chronic kidney disease and end-stage renal disease. Headquartered in Kentucky and founded in 1961, Humana Inc. (NYSE:HUM) only offers services in the US and ranks 4th in our list of the best dialysis and kidney disease stocks to buy. It recently signed an agreement with kidney care management company, Interwell Health, to enhance treatment plans for patients with chronic kidney disease as well as end-stage kidney disease. Humana Inc. (NYSE:HUM) posted EPS of $8.67 at the end of Q2.
After digging through 910 hedge funds for their June quarter of 2023 shareholdings, Insider Monkey found out that 70 had invested in Humana Inc. (NYSE:HUM). Rajiv Jain’s GQG Partners is the biggest investor among these because of its $1.3 billion stake.
3. The Cigna Group (NYSE:CI)
Number of Hedge Fund Holders In Q2 2023: 74
Market Capitalization: $92.1 Billion
The Cigna Group (NYSE:CI) was founded more than 200 years ago and is headquartered in Bloomfield, Connecticut. With a market capitalization of $92.1 billion, The Cigna Group (NYSE:CI) ranks 3rd in our list of the best dialysis and kidney disease stocks to buy. With a huge presence in the US, the company provides staff-assisted home hemodialysis services too for its patients. The Cigna Group (NYSE:CI) launched a Cigna Collaborative Care program for chronic kidney disease in 2016. It reported Q2 revenue of $48.6 billion and EPS of $6.13, beating analysts’ expectations of $5.98.
Insider Monkey’s research of Q2 2023 covering 910 hedge funds showed that 74 had owned The Cigna Group (NYSE:CI)’s shares. The firm’s largest stakeholder among these is Larry Robbins’ Glenview Capital as it owns $579.6 million worth of shares.
2. Merck & Co., Inc. (NYSE:MRK)
Number of Hedge Fund Holders In Q2 2023: 78
Market Capitalization: $266.1 Billion
New Jersey-based Merck & Co., Inc. (NYSE:MRK) was founded in 1891. It has been offering comprehensive medical plans and services since then globally. With a market capitalization of whopping $266 billion, Merck & Co., Inc. (NYSE:MRK) ranks 2nd in our list of the best dialysis and kidney disease stocks to buy. It received a fast track designation from the US Food and Drug Administration for the company’s investigational anticoagulant therapy MK-2060 to mitigate risk of thrombotic cardiovascular events in patients suffering from end-stage renal disease. Merck & Co., Inc. (NYSE:MRK) posted total revenue of $15 billion in Q2, that grew 14%.
As of June 2023, 78 out of the 910 hedge funds part of Insider Monkey’s database were Merck & Co., Inc. (NYSE:MRK)’s investors. The largest shareholder was AQR Capital Management in our database with its $331.8 million investment.
1. Thermo Fisher Scientific Inc. (NYSE:TMO)
Number of Hedge Fund Holders In Q2 2023: 103
Market Capitalization: $189 Billion
Thermo Fisher Scientific Inc. (NYSE:TMO) is a Waltham, Massachusetts-based life solutions firm that was incorporated in 1956. With a market capitalization of $189 billion, it tops our list of the best dialysis and kidney disease stocks to buy. Thermo Fisher Scientific Inc. (NYSE:TMO) offers dialysis treatment plans with 10 μL to 250 mL sample volumes. These devices do not require knots or clips and hence they reduce leaking and loss of sample.
It also agreed to acquire Olink Holding AB (publ) (NASDAQ:OLK) for $26 per American Depositary Share in cash to enhance its service offering. Thermo Fisher Scientific Inc. (NYSE:TMO) posted Q2 EPS of $5.51 beating analysts’ expectations of $5.42. Revenue for the quarter was $10.7 billion.
103 out of the 910 hedge funds surveyed by Insider Monkey had bought the firm’s shares in Q2 2023. Out of these, the firm’s largest investor is Chris Hohn’s TCI Fund Management since it owns 3.2 million shares that are worth $1.7 billion.
Disclosure: None. You can also take a look at 15 Best Healthcare Stocks To Buy Now and 10 Oversold Healthcare Stocks to Buy.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
